The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
RNAi-based modulation of IFN-γ signaling in skin
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational siRNA design for RNA interference
Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., & Khvorova, A. (2004) · Nature Biotechnology · doi:10.1038/nbt936 · Cited by 2,094
Self-citationTwo Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
Brown, C. R., Gupta, S., Qin, J., Racie, T., He, G., Lentini, S., Malone, R., Yu, M., Matsuda, S., Shulga-Morskaya, S., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa670 · Cited by 285
Alterman, J. F., Godinho, B. M. D. C., Hassler, M. R., Ferguson, C. M., Echeverria, D., Sapp, E., Haraszti, R. A., Coles, A. H., Conroy, F., Miller, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0205-0 · Cited by 227
Self-citationImproving siRNA Delivery In Vivo Through Lipid Conjugation
Osborn, M. F., & Khvorova, A. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0725 · Cited by 137
Self-citationVisualization of self-delivering hydrophobically modified siRNA cellular internalization
Ly, S., Navaroli, D. M., Didiot, M.-C., Cardia, J., Pandarinathan, L., Alterman, J. F., Fogarty, K., Standley, C., Lifshitz, L. M., Bellve, K. D., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1005 · Cited by 132
Self-citation
Research works printed but not linked: 46
- Ruffilli, 2019, MIG in cutaneous systemic lupus erythematosus, Clin. Ter, 170, e71
- Rork, 2016, Understanding autoimmunity of vitiligo and alopecia areata, Curr. Opin. Pediatr., 28, 463, 10.1097/MOP.0000000000000375 · DOI
- Harris, 2012, A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin, J. Invest. Dermatol., 132, 1869, 10.1038/jid.2011.463 · DOI · Paper page
- Shao, 2019, IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus, Sci. Transl. Med., 11, eaav7561, 10.1126/scitranslmed.aav7561 · DOI · Paper page
- Rashighi, 2014, CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo, Sci. Transl. Med., 6, 223ra23, 10.1126/scitranslmed.3007811 · DOI · Paper page
- Richmond, 2017, Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease, J. Invest. Dermatol., 137, 350, 10.1016/j.jid.2016.09.016 · DOI · Paper page
- Richmond, 2017, CXCR3 depleting antibodies prevent and reverse vitiligo in mice, J. Invest. Dermatol., 137, 982, 10.1016/j.jid.2016.10.048 · DOI · Paper page
- van den Boorn, 2009, Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients, J. Invest. Dermatol., 129, 2220, 10.1038/jid.2009.32 · DOI · Paper page
- Xing, 2014, Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition, Nat. Med., 20, 1043, 10.1038/nm.3645 · DOI · Paper page
- Kennedy Crispin, 2016, Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata, JCI Insight, 1, e89776, 10.1172/jci.insight.89776 · DOI · Paper page
- King, 2022, Two phase 3 trials of Baricitinib for alopecia areata, N. Engl. J. Med., 386, 1687, 10.1056/NEJMoa2110343 · DOI · Paper page
- Rothstein, 2017, Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib, J. Am. Acad. Dermatol., 76, 1054, 10.1016/j.jaad.2017.02.049 · DOI · Paper page
- Rosmarin, 2020, Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial, Lancet, 396, 110, 10.1016/S0140-6736(20)30609-7 · DOI · Paper page
- Schwartz, 2017, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases, Nat. Rev. Drug Discov., 16, 843, 10.1038/nrd.2017.201 · DOI · Paper page
- Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888 · DOI · Paper page
- Khvorova, 2017, The chemical evolution of oligonucleotide therapies of clinical utility, Nat. Biotechnol., 35, 238, 10.1038/nbt.3765 · DOI · Paper page
- Scott, 2020, Givosiran: first approval, Drugs, 80, 335, 10.1007/s40265-020-01269-0 · DOI · Paper page
- Scott, 2021, Lumasiran: first approval, Drugs, 81, 277, 10.1007/s40265-020-01463-0 · DOI · Paper page
- Lamb, 2021, Inclisiran: first approval, Drugs, 81, 389, 10.1007/s40265-021-01473-6 · DOI · Paper page
- Biscans, 2019, Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo, Nucleic Acids Res., 47, 1082, 10.1093/nar/gky1239 · DOI · Paper page
- Biscans, 2019, The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo, J. Control Release, 302, 116, 10.1016/j.jconrel.2019.03.028 · DOI
- Biscans, 2021, Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles, Mol. Ther., 29, 1382, 10.1016/j.ymthe.2020.12.023 · DOI
- Birmingham, 2007, A protocol for designing siRNAs with high functionality and specificity, Nat. Protoc., 2, 2068, 10.1038/nprot.2007.278 · DOI · Paper page
- Shmushkovich, 2018, Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs, Nucleic Acids Res., 46, 10905, 10.1093/nar/gky745 · DOI
- Hassler, 2018, Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo, Nucleic Acids Res., 46, 2185, 10.1093/nar/gky037 · DOI · Paper page
- Moran, 2012, Incyte comes of age with JAK inhibitor approval, Nat. Biotechnol., 30, 3, 10.1038/nbt0112-3 · doi:10.1038/nbt0112-3
- Roberts, 2020, Advances in oligonucleotide drug delivery, Nat. Rev. Drug Discov., 19, 673, 10.1038/s41573-020-0075-7 · DOI · Paper page
- Valente, 1992, Distribution of interferon-gamma receptor in human tissues, Eur. J. Immunol., 22, 2403, 10.1002/eji.1830220933 · DOI · Paper page
- Hu, 2009, Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases, Immunity, 31, 539, 10.1016/j.immuni.2009.09.002 · DOI · Paper page
- Ivashkiv, 2018, IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy, Nat. Rev. Immunol., 18, 545, 10.1038/s41577-018-0029-z · DOI · Paper page
- Seung, 2011, Inhibiting CXCR3-dependent CD8+ T cell trafficking enhances tolerance induction in a mouse model of lung rejection, J. Immunol., 186, 6830, 10.4049/jimmunol.1001049 · DOI
- Groom, 2012, CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation, Immunity, 37, 1091, 10.1016/j.immuni.2012.08.016 · DOI · Paper page
- Ledford, 2018, Gene-silencing technology gets first drug approval after 20-year wait, Nature, 560, 291, 10.1038/d41586-018-05867-7 · DOI · Paper page
- Maouia, 2017, Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients, Pigment Cell Melanoma Res, 30, 259, 10.1111/pcmr.12559 · DOI
- Ferguson, 2020, Cell type impacts accessibility of mRNA to silencing by RNA interference, Mol. Ther. Nucleic Acids, 21, 384, 10.1016/j.omtn.2020.06.006 · DOI
- Małecka, 2020, Ribosomes clear the way for siRNA targeting, Nat. Struct. Mol. Biol., 27, 775, 10.1038/s41594-020-0495-4 · DOI
- Jouanguy, 1997, Infections in IFNGR-1-deficient children, J. Interferon Cytokine Res., 17, 583, 10.1089/jir.1997.17.583 · DOI
- Jouanguy, 1999, A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection, Nat. Genet., 21, 370, 10.1038/7701 · DOI · Paper page
- van de Vosse, 2017, IFN-γR1 defects: mutation update and description of the IFNGR1 variation database: van de VOSSE and van DISSEL, Hum. Mutat., 38, 1286, 10.1002/humu.23302 · DOI
- Horras, 2011, Regulation of hepatocyte fate by interferon-γ, Cytokine Growth Factor Rev., 22, 35, 10.1016/j.cytogfr.2011.01.001 · DOI
- Mohammadi, 2021, CC and CXC chemokines play key roles in the development of polyomaviruses related pathological conditions, Virol. J., 18, 111, 10.1186/s12985-021-01582-4 · DOI
- Prausnitz, 2017, Engineering microneedle patches for vaccination and drug delivery to skin, Annu. Rev. Chem. Biomol. Eng., 8, 177, 10.1146/annurev-chembioeng-060816-101514 · DOI · Paper page
- Tadros, 2020, STAR particles for enhanced topical drug and vaccine delivery, Nat. Med., 26, 341, 10.1038/s41591-020-0787-6 · DOI
- Dharamdasani, 2020, Topical delivery of siRNA into skin using ionic liquids, J. Control Release, 323, 475, 10.1016/j.jconrel.2020.04.038 · DOI
- Mandal, 2020, Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations, Sci. Adv., 6, eabb6049, 10.1126/sciadv.abb6049 · DOI
- Turanov, 2018, RNAi modulation of placental sFLT1 for the treatment of preeclampsia, Nat. Biotechnol., 36, 1164, 10.1038/nbt.4297 · DOI · Paper page
Cited by
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Self-citation
Metadata
- Authors
- Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D. A., Vangjeli, L., Monopoli, K., Okamura, K., Biscans, A., Clauss, A., Harris, J. E., & Khvorova, A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 30
- Issue
- 8
- Pages
- 2709-2721
- ISSN
- 1525-0016
- Cited by
- 33
- References
- 9
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RNAi-based modulation of IFN-γ signaling in skin. https://app.cochat.ai/papers/10.1016/j.ymthe.2022.04.019
- The paper
- Tang, Q., Sousa, J., Echeverria, D., Fan, X., Hsueh, Y.-C., Afshari, K., MeHugh, N., Cooper, D. A., Vangjeli, L., Monopoli, K., Okamura, K., Biscans, A., Clauss, A., Harris, J. E., & Khvorova, A. (2022). RNAi-based modulation of IFN-γ signaling in skin. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2022.04.019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.